« Back to Record
Citation APA

Paridaens, R., Roy, J. A., Nooij, M., Klijn, J., Houston, S., Beex, L., Vinholes, J., Tomiak, E., Van Vreckem, A., Langenaeken, C., van Glabbeke, M., & Piccart-Gebhart, M. (1998). Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group. Anti-cancer drugs, 9(1), 29-35.


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/59577

Paridaens, R., Roy, J. A., Nooij, M., Klijn, J., Houston, S., Beex, L., Vinholes, J., Tomiak, E., Van Vreckem, A., Langenaeken, C., van Glabbeke, M., & Piccart-Gebhart, M. (1998). Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group. Anti-cancer drugs, 9(1), 29-35.